Treatment of migraine
AssigneeAllergan Pharmaceuticals International Limited
InventorsJoel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Claims15
1-3. (canceled)
A method for the acute treatment of migraine with or without aura in a patient having hepatic impairment, the method comprising:
- determining whether the patient has mild, moderate, or severe hepatic impairment;
- and
- if the patient has mild hepatic impairment, administering 50 mg or 100 mg ubrogepant to the patient;
- if the patient has moderate hepatic impairment, administering 50 mg or 100 mg ubrogepant to the patient;
- and
- if the patient has severe hepatic impairment, administering 50 mg ubrogepant to the patient.
7-9. (canceled)
A method for the acute treatment of migraine with or without aura in a patient having renal impairment, the method comprising:
- determining whether the patient has mild renal impairment, moderate renal impairment, severe renal impairment, or end-stage renal disease;
- and
- if the patient has mild renal impairment, administering 50 mg or 100 mg ubrogepant to the patient;
- if the patient has moderate renal impairment, administering 50 or 100 mg ubrogepant to the patient;
- if the patient has severe renal impairment, administering 50 mg ubrogepant to the patient;
- and
- if the patient has end-stage renal disease, avoiding administration of ubrogepant to the patient.
A method for the acute treatment of migraine with or without aura in a patient undergoing treatment with a weak or moderate CYP3A4 inducer, the method comprising administering 100 mg ubrogepant to the patient undergoing treatment with the weak or moderate CYP3A4 inducer.
The method of claim 14, wherein the second dose is administered between 2 and 24 hours after the first dose of ubrogepant.
A method for the acute treatment of migraine with or without aura in a patient undergoing concurrent treatment with a BCRP and/or P-gp only inhibitor, the method comprising administering 50 mg ubrogepant to the patient undergoing treatment with a BCRP and/or P-gp only inhibitor.
Dependencies are inferred from the claim text.